Vaccine Safety Registry
HPV Vaccine Safety
Evidence-based safety information on HPV vaccines. Clinical data for Gardasil 9, dosing schedules, and long-term surveillance metadata.
Medically reviewed by
Dr. Aarti Ghosh, MBBS, MD (General Medicine), DM (Clinical Immunology)
View Clinical ProfileOpen Access Clinical Intelligence for All Readers
HCP Connect provides publicly accessible vaccine-safety information for healthcare professionals, patients, caregivers, researchers, and the wider public. Access to this Vaccine Safety Monograph does not require an account, registration, or NPI verification.
Translate this vaccine safety monograph into your preferred language:
Automated translation provided for accessibility · English version is the authoritative clinical record.
Clinical Overview
Professional summary
Human papillomavirus (HPV) is a highly prevalent viral module capable of inducing oncogenic changes. Persistent high-risk HPV infections are the primary drivers of cervical, vaginal, vulvar, penile, anal, and oropharyngeal malignancies.
Registry immunizations are verified to prevent over 90% of cancers associated with specific high-risk viral nodes. Clinical efficacy is maximized when protocols are finalized prior to potential viral exposure.
Vaccine Formulations
Module specifics & formulations
Formulation Node
Gardasil 9
Merck & Co. | 9-Valent Protocol
- Strains protected: HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.
- Target cohort: Approved for individuals ages 9-45 years.
- Indication: Prevention of oncogenic malignancies and condyloma acuminata.
- Administration: 2 or 3-dose titration based on age at protocol initiation.
Clinical Triage
Eligibility & contraindications
Routine Protocol
- Pediatric cohorts (11-12 years)
- Catch-up immunization through age 26
- Optional initiation at age 9
Special Triage
- Adults 27-45: shared clinical decision-making
- Immunocompromised clinical profiles
- Men who have sex with men (MSM)
Absolute & Relative Contraindications
- Anaphylaxis to previous HPV protocol dose
- Acute moderate-to-severe febrile illness
- Gestational status is typically deferred, although not treated as an absolute contraindication
Adverse Events
Reported reactions & surveillance
Local Reactions
- Localized pain
- Erythema
- Induration (Swelling)
Systemic Profile
- Pyrexia (Fever)
- Cephalalgia (Headache)
- Nausea
- Generalized fatigue
Surveillance Analytics
Post-market surveillance metrics
135M+
Doses Distributed
15+ Years
Real-World Data
73,000
Trial Participants
Global Surveillance Synthesis
Independent global reviews by multiple country-specific organizations and the WHO continue to validate the exemplary safety profile and high oncogenic prevention efficacy of HPV registry modules.
Editorial Governance
Clinical Reviewers & Authors
Dr. Priya Kapoor
MBBS, MS (Obstetrics & Gynaecology)
Obstetrics & Gynecology
Dr. Aarti Ghosh
MBBS, MD (General Medicine), DM (Clinical Immunology)
Clinical Immunology
All vaccine safety monographs are authored and reviewed by credentialed medical specialists in infectious disease, immunology, and pediatrics.
Browse All Clinical Authors & Medical Reviewers DirectoryEvidence Base
Sources & References
The clinical guidance, contraindications, and safety surveillance statistics in this monograph are synthesized directly from authoritative public health agencies, regulatory package inserts, and peer-reviewed clinical studies:
- 1CDC2024Human Papillomavirus Vaccination for Adults: Updated Recommendations of the ACIP
MMWR Morbidity and Mortality Weekly Report, 68(32):698-702
- 2WHO2024Human papillomavirus vaccines: WHO position paper — December 2022
Weekly Epidemiological Record, 97(50):645-672
- 3FDA2024GARDASIL 9 (Human Papillomavirus 9-valent Vaccine) Prescribing Information
U.S. Food and Drug Administration CBER, Merck & Co.
- 4Lancet2023The effects of the national HPV vaccination programme in England: a post-licensure evaluation
The Lancet, 398(10316):2084-2096
Cite & Reference This Monograph
Content Licensing & Governance
Content Licensing & Reuse Policy
HCP Connect. Content licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0). See our Content Licensing & Reuse Policy for details.
Authored by Dr. Priya Kapoor and clinically reviewed by Dr. Aarti Ghosh, in alignment with HCP Connect Clinical Faculty & Reviewers Directory. Content verified against 2026 CDC ACIP and WHO SAGE safety protocols.
Vaccine Safety Enquiries & Direct Response
HCP Connect welcomes clinical questions, public health inquiries, and feedback regarding our vaccine safety monographs. Our clinical editorial staff and medical reviewers actively monitor all incoming communications.
Guaranteed Enquiry Response Timeline
We commit to responding in writing to all clinical and public enquiries within 2–3 business days (guaranteed within 5 calendar days, well within the 10 calendar day international assessment standard). Urgent clinical sourcing corrections are triaged within 24 hours.